Outbreaks of Ebola virus disease are caused by multiple virus species although current therapeutic monoclonal antibodies (mAb) are essentially limited to treating one species, Zaire ebolavirus. In this issue of Immunity, Gilchuk etÂ al. (2018) identify new mAbs with potent cross-neutralizing activity against three ebolavirus species pathogenic to humans.